Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael T Stumpp

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2020
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid TumorsRichard D Baird, Constanza Linossi, Mark Middleton, et al.
Mabs|October 17, 2017
Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidateH Kaspar Binz, Talitha R Bakker, Douglas J Phillips, et al.
British Journal of Clinical Pharmacology|April 14, 2023
Ensovibep, a SARS-CoV-2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first-in-human, ascending single-dose Phase 1 studyNina Stojcheva, Stacy Gladman, Marianne Soergel, et al.
Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Open Forum Infectious Diseases|June 10, 2024
The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 StudyJeff Kingsley, Nagalingeswaran Kumarasamy, Luis Abrishamian, et al.
Nature Biotechnology|July 21, 2022
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variantsSylvia Rothenberger, Daniel L Hurdiss, Marcel Walser, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2020
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid TumorsRichard D Baird, Constanza Linossi, Mark Middleton, et al.
Mabs|October 17, 2017
Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidateH Kaspar Binz, Talitha R Bakker, Douglas J Phillips, et al.
British Journal of Clinical Pharmacology|April 14, 2023
Ensovibep, a SARS-CoV-2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first-in-human, ascending single-dose Phase 1 studyNina Stojcheva, Stacy Gladman, Marianne Soergel, et al.
Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Open Forum Infectious Diseases|June 10, 2024
The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 StudyJeff Kingsley, Nagalingeswaran Kumarasamy, Luis Abrishamian, et al.
Nature Biotechnology|July 21, 2022
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variantsSylvia Rothenberger, Daniel L Hurdiss, Marcel Walser, et al.
Pageof 3